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Isolated noncompaction of the ventricular myocardium (INVM) is an uncommon cardiomyopathy char-
acterized by the persistence of fetal myocardium with prominent trabecular meshwork and deep intertra-
becular recesses, often associated with systolic dysfunction and ventricular dilatation. A 23-year-old man
fromBurkina Faso was referred to our operative unit with a diagnosis of INVM,made with echocardiogram
and magnetic resonance imaging and nonsustained ventricular tachycardia. The literature reports the in-
cidence of malignant ventricular arrhythmias in as many as 47% of the patients and sudden cardiac death
in almost 50% of them and this supported our decision to perform implantable cardioverter-defibrillators
implantation. (PACE 2009; 32:1092–1095)
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Introduction
Isolated noncompaction of the ventricular
myocardium (INVM), also known as “spongy
myocardium,” is an uncommon cardiomyopa-
thy characterized by the persistence of fetal my-
ocardiumwith excessive prominence of trabecular
meshwork and deep intertrabecular recesses and
is caused by the interruption of the normal pro-
cess of endomyocardial and myocardial morpho-
genesis. These features are also associated with
systolic dysfunction and ventricular dilatation.1–3
Echocardiography is the gold standard procedure
for diagnosis. In the largest series of patients with
INVM, the prevalence of those referred to echocar-
diography laboratory and describing similar find-
ings was 0.014%; men were more affected than
women.4 Clinical manifestations ranging from no
symptoms to congestive heart failure, systemic
thromboemboli, and also arrhythmias and sudden
cardiac death (SCD).1–3
Implantation of implantable cardioverter-
defibrillators (ICD) in these patients is a treatment
option, but data on long-term follow-up are lim-
ited. The aim of this case report was to analyze the
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management of a patient with INVM undergoing
ICD implantation.
Case Report
A 23-year-old man from Burkina Faso was re-
ferred to our unit with a diagnosis of INVM based
upon echocardiography and cardiac magnetic res-
onance imaging (MRI) performed after a history of
decreased exercise tolerance and palpitations. The
first surface electrocardiogram (ECG) showed si-
nus rhythm, normal QRS duration, left ventricular
hypertrophy, early repolarization, T-wave “labil-
ity,” and negative U wave in V5–V6 leads; the 24-
hour ECG Holter monitoring showed sinus brady-
cardia, frequent episodes of ventricular bigemi-
nism, and nonsustained ventricular tachycardia
(NSVT). Echocardiographic evaluation showed
left ventricle dilatation (end-diastolic volume
180 mL), normal wall thickening (interventricular
septum and posterior wall 10 mm), widespread
left ventricular hypokinesis with a left ventricle
ejection fraction (LVEF) of 35%, heavy trabecula-
tion of the left ventricle’s apical and lateral wall,
while the left atrium, aortic root, right chambers,
and inferior cava vein were normal; color Doppler
displayed normal diastolic filling pattern, mild-
to-moderate grade mitral regurgitation, and mild
grade tricuspidal regurgitation in the absence of
pulmonary hypertension. Neither interventricular
nor intraventricular dyssynchrony was described.
Basal and contrast-enhanced MRI confirmed the
presence of trabeculation and intertrabecular
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Figure 1. Long-axis (A) and short-axis (B) cardiac MRI showing apical and anterolateral trabec-
ular meshwork and deep intertrabecular recesses.
recesses as well as global hypokinesis (EF 27%)
and an increased left ventricle volume (Fig. 1).
Several episodes of asymptomatic NSVT occurred
while performing the MRI Virus isolation, previ-
ously performed, was negative; the coronaroven-
triculography showed normal vessels and non-
compaction of the left ventricle. According to
all these findings and the clinical manifesta-
tions of the disease, the patient received aspirin,
carvedilol, and enalapril drug therapy and was
referred to our unit to evaluate a possible ICD
implantation for primary prevention of SCD as a
bridge to heart transplant.
Upon admission, 3 months after the diagno-
sis of INMV, the patient was in good hemody-
namic conditions and in New York Heart Associa-
tion (NYHA) class II. We performed a surface ECG
(Fig. 2) and an echocardiogram that confirmed the
previous results, except for the LVEF that we had
estimated as 30%; this could, however, be caused
by disease progression or operator-dependent vari-
ability (Fig. 3). All routine blood tests were nor-
mal, and the ECG monitoring performed during
the patient’s stay in our intensive care unit before
ICD implantation showed persistent sinus brady-
cardia and short runs of atrial tachycardia.
In summary, the patient was in NYHA class
II and was affected by INVM. The ICD implanta-
tion guidelines showed a class II (evidence level
B) indication according to the recent Italian Asso-
ciation of Arrhythmology and Cardiostimulation
guidelines, although considering LVEF, the pa-
tient was a class I (evidence level B) according
to the American College of Cardiology/American
Heart Association/European Society of Cardiology
(ACC/AHA/ESC) guidelines for the management
of ventricular arrhythmia (VA) patients and SCD
prevention.5,6 We performed an electrophysiolog-
ical (EP) study in which the VA induction pro-
tocol included programmed stimulation at three
basic cycle lengths (500, 400, and 330 ms) and
up to three extrastimuli with a minimum cou-
pling interval of 200 ms from two sites in the
right ventricle (apex and outflow tract); a third ex-
trastimulus was introduced during a basic drive
cycle length of minimal 500 ms after completion
of programmed ventricular stimulation with one
and two extrastimuli during paced cycle lengths
of 500, 400, and 330 ms. We observe no sustained
ventricular tachycardia or fibrillation during the
test, but our decision to perform ICD implantation
was supported by literature data reporting a pres-
ence of supraventricular arrhythmias and an inci-
dence of malignant VA in as many as 47% of the
patients and SCD in almost 50% of the patients for
an adult population of INMV patients.1,3,7 Because
of the high prevalence of supraventricular tach-
yarrhythmias in these patients and based on our
patient’s persistent sinus bradycardia and need
for β-blockers, we opted for a dual-chamber de-
vice. The patient was discharged with indications
for a clinical follow-up and monitoring for po-
tential need of a heart transplant. Upon the first
ICD check, 1 month after implantation, no sus-
tained VAs were recorded; the patient was in a
good hemodynamic state and was still in NYHA
class II.
Discussion
According to literature data of last 20 years,
clinical manifestations of INVM vary from asymp-
tomatic to heart failure, systemic thromboemboli,
arrhythmias, and SCD.While medical treatment of
heart failure is established by international guide-
lines, less consensus exists on the treatment of
ventricular and supraventricular arrhythmias in
this cohort of patients. According to the published
data, the incidence of malignant VA is reported in
as many as 47% and SCD in 50% of adults affected
by INVM1,3,7; a better prognoses is reported in the
pediatric population.3,8
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Figure 2. Patient’s surface ECG.
Figure 3. INVM echocardiographic finding.
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A recent study conducted on an adult pop-
ulation seems to reduce the arrhythmogenic role
of this cardiomyopathy even in the presence of
left ventricle systolic dysfunction.9 On the con-
trary, other recent evidences demonstrates a po-
tential arrhythmogenic role in patients with INVM
who underwent ICD implantation for secondary
and primary prevention. In particular, Kobza et al.
and Duru et al. showed how potentially life-
threatening VA may occur in these patients and
how ICD therapy may be effective also for those
who did not show sustained ventricular tachy-
cardia or fibrillation during EP study.10,11 Simi-
larly, Sato et al. illustrated how fatal VA might
occur in INVM in the absence of left ventricular
dysfunction and/or clinical evidence of myocar-
dial ischemia.12 It should be underlined, how-
ever, that VA have been associated with mortal-
ity in idiopathic dilated cardiomyopathy, and in
some studies, increased ventricular volumes and
impaired EF have put patients at a higher risk for
SCD.13
All the three main mechanisms of arrhythmo-
genesis, reentry, trigger activity, and automatism,
have been implicated in the genesis of VA in pa-
tients with IDC. Moreover, these arrhythmogenic
substrates are often potentiated by electrolyte im-
balance secondary to diuretic treatment or con-
comitant renal failure, by antiarrhythmic drugs,
or by bradycardia.14 In INVM patients, myocardial
macroreentry is probably the mechanism respon-
sible for VA, probably because trabecular mesh-
work and deep intertrabecular recesses represent
a good anatomic substrate for its onset. In our
opinion, it is extremely hard to establish a cor-
rect stratification of the arrhythmogenic risk in
these patients, not only because INVM is an un-
common disease but also because patients are of-
ten affected by asymptomatic systolic dysfunc-
tion, representing an independent risk factor for
SCD. Also, in our opinion, the 24-hour Holter
monitoring is not the most appropriate diagnos-
tic tool for arrhythmias in this small cohort of pa-
tients. A prolonged monitoring by means of a loop
recorder would most likely provide us with better
information.9
Conclusion
VA and SCD are described in patients affected
by INVM. The disease’s low prevalence and the
limited data available in literature do not allow
to reasonably establish the prognosis of these pa-
tients; also, the therapeutic treatment is left to
the individual physician and to his/her medical
knowledge. On the basis of the young age of the
patient, the history of NSVT, and the systolic dys-
function and also supported by the current guide-
lines,5,6 we decided to perform ICD implantation.
We consider our patient to be at a high risk for
SCD and ICD was not only a life-saving treatment
for his condition but also a bridge to a potential
heart transplant.
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